Summit Therapeutics (SMMT) Gains from Investment Securities (2019 - 2025)
Historic Gains from Investment Securities for Summit Therapeutics (SMMT) over the last 8 years, with Q3 2025 value amounting to $856000.0.
- Summit Therapeutics' Gains from Investment Securities changed N/A to $856000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 740.04%. This contributed to the annual value of $4.2 million for FY2024, which is 68.32% down from last year.
- Per Summit Therapeutics' latest filing, its Gains from Investment Securities stood at $856000.0 for Q3 2025.
- Summit Therapeutics' Gains from Investment Securities' 5-year high stood at $4.2 million during Q2 2023, with a 5-year trough of $104000.0 in Q4 2022.
- Over the past 5 years, Summit Therapeutics' median Gains from Investment Securities value was $1.3 million (recorded in 2021), while the average stood at $1.9 million.
- As far as peak fluctuations go, Summit Therapeutics' Gains from Investment Securities soared by 12660000.0% in 2021, and later crashed by 9177.87% in 2022.
- Summit Therapeutics' Gains from Investment Securities (Quarter) stood at $1.3 million in 2021, then plummeted by 91.78% to $104000.0 in 2022, then surged by 3981.73% to $4.2 million in 2023, then dropped by 0.68% to $4.2 million in 2024, then tumbled by 79.7% to $856000.0 in 2025.
- Its Gains from Investment Securities stands at $856000.0 for Q3 2025, versus $2.3 million for Q2 2025 and $1.4 million for Q1 2025.